HB-adMSCs

PreclinicalBiologic

HB-adMSCs is one of 247 biologic programs targeting Chronic Inflammatory Demyelinating Polyneuropathy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

246

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Inflammatory Demyelinating PolyneuropathyActive, not recruiting

Systemic Lupus ErythematosusActive, not recruiting

Cerebral PalsyActive, not recruiting

Muscular DystrophyActive, not recruiting

StrokeActive, not recruiting

Amyotrophic Lateral SclerosisActive, not recruiting

Pancreatic CancerActive, not recruiting

PolyneuropathyActive, not recruiting

Spinal Cord InjuryActive, not recruiting

Chronic Inflammatory Demyelinating PolyneuropathyPreclinical

Active, not recruiting

Systemic Lupus ErythematosusPreclinical

Active, not recruiting

Cerebral PalsyPreclinical

Active, not recruiting

Muscular DystrophyPreclinical

Active, not recruiting

StrokePreclinical

Active, not recruiting

Amyotrophic Lateral SclerosisPreclinical

Active, not recruiting

Pancreatic CancerPreclinical

Active, not recruiting

PolyneuropathyPreclinical

Active, not recruiting

Spinal Cord InjuryPreclinical

Active, not recruiting

Competition

Competitive Landscape

335 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

Medrol

Pfizer

Preclinical

1 2

Byetta

AstraZeneca

Preclinical

1 3

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 4

Ayvakit Sprinkle

MMemorial Sloan Kettering Cancer Center

Preclinical

1 5

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 6

Active Comparator

Moderna

Preclinical

1 7

Sulfonylureas

Eli Lilly

Preclinical

1 8

HB-adMSCs

HHope Biosciences Research Foundation

Preclinical

1 9

Hyperpolarized 13c Pyruvate

UUniversity of Maryland, Baltimore

Preclinical

1 10

PEG-Rhg-CSF

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

COVID-194 trials

Intermediate Size Expanded Access Protocol for the Treatment of Post-COVID-19 Syndrome

No longer available·HHope Biosciences Research Foundation··NCT04798066

A Clinical Trial to Determine the Safety and Efficacy of HB-adMSCs to Provide Protection Against COVID-19

Completed·HHope Biosciences Research Foundation·Phase 2·NCT04349631·51 enrolled

A Randomized, Double-Blind, Single Center, Efficacy and Safety Study of Allogeneic HB-adMSCs Against COVID-19.

Completed·HHope Biosciences Research Foundation·Phase 2·NCT04348435·53 enrolled

Show 1 more trial

Randomized Double-Blind Phase 2 Study of Allogeneic HB-adMSCs for the Treatment of Chronic Post-COVID-19 Syndrome

Completed·HHope Biosciences Research Foundation·Phase 2·NCT05126563·79 enrolled

Parkinson's Disease2 trials

Randomized, Double-Blind Clinical Trial for Parkinson's Disease (Early and Moderate)

Completed·HHope Biosciences Research Foundation·Phase 2·NCT04928287·24 enrolled

Intermediate Size Patient Population Expanded Access IND for the Treatment of Patients With Parkinson's Disease.

No longer available·HHope Biosciences Research Foundation··NCT04772378

Rheumatoid Arthritis1 trial

Phase 1/2a Clinical Trial to Assess the Safety of HB-adMSCs for the Treatment of Rheumatoid Arthritis

Completed·HHope Biosciences LLC·Phase 1/2·NCT03691909·15 enrolled

Mesenchymal Stem Cells1 trial

Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Treatment of SCI

No longer available·HHope Biosciences LLC··NCT03925649

Stroke1 trial

Individual Patient Expanded Access IND for the Treatment of Stroke

No longer available·HHope Biosciences Research Foundation··NCT04907188

12 more indications

Chronic Inflammatory Demyelinating Polyneuropathy1 trial

An Expanded Access IND for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

No longer available·HHope Biosciences Research Foundation··NCT04825626

Encephalopathy1 trial

A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy for the Treatment of Traumatic Brain Injury and Hypoxic-Ischemic Encephalopathy

Completed·HHope Biosciences LLC·Phase 1/2·NCT04063215·24 enrolled

Polyneuropathy1 trial

Individual Patient Expanded Access IND to Treat Polyneuropathy

No longer available·HHope Biosciences Research Foundation··NCT04064983

ESS1 trial

"Individual Patient Expanded Access IND to Treat Primary Lateral Sclerosis"

No longer available·HHope Biosciences Research Foundation··NCT04825613

Multiple Sclerosis1 trial

Randomized Double-Blind Phase 2 Efficacy and Safety of Autologous HB-MSCs vs Placebo for Treatment of Multiple Sclerosis

Completed·HHope Biosciences Research Foundation·Phase 2·NCT05116540·24 enrolled

Pancreatic Cancer1 trial

Individual Patient Expanded Access IND of Hope Biosciences First Blood Relative Allogeneic Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) for Pancreatic Cancer

No longer available·HHope Biosciences LLC··NCT04087889

Muscular Dystrophy1 trial

HBCMD01- Expanded Access for the Treatment of Congenital Muscular Dystrophy.

No longer available·HHope Biosciences Research Foundation··NCT05154851

Mesenchymal Stem Cell1 trial

A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) for the Treatment of Alzheimer's Disease

Withdrawn·HHope Biosciences LLC·Phase 1/2·NCT04228666

Amyotrophic Lateral Sclerosis1 trial

Individual Patient Expanded Access IND of Autologous HBadMSCs for the Treatment of Amyotrophic Lateral Sclerosis

No longer available·HHope Biosciences Research Foundation··NCT04514952

Cerebral Palsy1 trial

Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for the Treatment of Cerebral Palsy

No longer available·HHope Biosciences Research Foundation··NCT04029896

Spinal Cord Injury1 trial

Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Spinal Cord Injury

No longer available·HHope Biosciences Research Foundation··NCT04064957

Systemic Lupus Erythematosus1 trial

Individual Patient Expanded Access IND of Autologous HB-adMSCs for the Treatment of Systemic Lupus Erythematosus (SLE)

No longer available·HHope Biosciences Research Foundation··NCT04907175

Sources

References

[1]
ClinicalTrials.gov — 21 trial records for HB-adMSCs. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HB-adMSCs compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HB-adMSCs. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hope Biosciences Research Foundation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: HHope Biosciences Research Foundation

HB-adMSCs

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

COVID-194 trials

Parkinson's Disease2 trials

Rheumatoid Arthritis1 trial

Mesenchymal Stem Cells1 trial

Stroke1 trial

Chronic Inflammatory Demyelinating Polyneuropathy1 trial

Encephalopathy1 trial

Polyneuropathy1 trial

ESS1 trial

Multiple Sclerosis1 trial

Pancreatic Cancer1 trial

Muscular Dystrophy1 trial

Mesenchymal Stem Cell1 trial

Amyotrophic Lateral Sclerosis1 trial

Cerebral Palsy1 trial

Spinal Cord Injury1 trial

Systemic Lupus Erythematosus1 trial

References

Drug Info

Quick Facts

Related News